- Home
- GRAF vs VYGR Comparison
GRAF vs VYGR Comparison
Compare GRAF & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRAF
- VYGR
- Stock Information
- Founded
- GRAF 2021
- VYGR 2013
- Country
- GRAF United States
- VYGR United States
- Employees
- GRAF N/A
- VYGR N/A
- Industry
- GRAF
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- GRAF
- VYGR Health Care
- Exchange
- GRAF NYSE
- VYGR Nasdaq
- Market Cap
- GRAF 288.9M
- VYGR 309.7M
- IPO Year
- GRAF 2024
- VYGR 2015
- Fundamental
- Price
- GRAF $10.07
- VYGR $6.45
- Analyst Decision
- GRAF
- VYGR Strong Buy
- Analyst Count
- GRAF 0
- VYGR 9
- Target Price
- GRAF N/A
- VYGR $16.44
- AVG Volume (30 Days)
- GRAF 42.1K
- VYGR 570.6K
- Earning Date
- GRAF 01-01-0001
- VYGR 11-12-2024
- Dividend Yield
- GRAF N/A
- VYGR N/A
- EPS Growth
- GRAF N/A
- VYGR N/A
- EPS
- GRAF 0.25
- VYGR 0.47
- Revenue
- GRAF N/A
- VYGR $163,784,000.00
- Revenue This Year
- GRAF N/A
- VYGR N/A
- Revenue Next Year
- GRAF N/A
- VYGR N/A
- P/E Ratio
- GRAF $40.59
- VYGR $13.83
- Revenue Growth
- GRAF N/A
- VYGR 3.40
- 52 Week Low
- GRAF $9.03
- VYGR $5.19
- 52 Week High
- GRAF $11.02
- VYGR $11.72
- Technical
- Relative Strength Index (RSI)
- GRAF N/A
- VYGR 51.85
- Support Level
- GRAF N/A
- VYGR $6.13
- Resistance Level
- GRAF N/A
- VYGR $7.44
- Average True Range (ATR)
- GRAF 0.00
- VYGR 0.34
- MACD
- GRAF 0.00
- VYGR 0.09
- Stochastic Oscillator
- GRAF 0.00
- VYGR 56.00
About GRAF GRAF GLOBAL CORP
Graf Global Corp is a blank check company.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.